Tabula Rasa HealthCare stock faces uncertainty after delisting and bankruptcy proceedings

The Tabula Rasa HealthCare stock (ISIN: US89400K1088) has been delisted from Nasdaq following Chapter 11 bankruptcy filing. Investors in Germany, Austria, and Switzerland should monitor developments as liquidation risks impact any remaining value. No active trading occurs on major exchanges.

Tabula Rasa HealthCare, once a leader in medication management technology for healthcare providers, filed for Chapter 11 bankruptcy protection in early 2023. The company, listed under ISIN US89400K1088 on Nasdaq, was delisted shortly after. This development ended public trading of its common shares, leaving investors with holdings of uncertain value. For DACH investors, the case highlights risks in U.S. healthcare tech amid rising interest rates and sector pressures.

As of: 23.03.2026

By Dr. Elena Voss, Senior Healthcare Equity Analyst – Tracking U.S. medtech firms' restructuring paths and their echoes in European portfolios.

Company Background and the Path to Bankruptcy

Tabula Rasa HealthCare provided software solutions to optimize medication regimens, targeting pharmacies, hospitals, and health plans. Founded in 2013, it went public in 2017 on Nasdaq under ticker TRHC. The firm specialized in pharmacogenomics and dose-decision support, aiming to reduce adverse drug events.

Revenue grew rapidly post-IPO, peaking above $300 million annually by 2021. Acquisitions like DoseMe and Medalogix bolstered its tech stack. However, heavy debt from buyouts and integration costs strained finances. By late 2022, liquidity issues surfaced amid a tough funding environment.

The bankruptcy filing on November 14, 2022, cited unsustainable debt levels exceeding $500 million against assets around $200 million. Management pursued a sale process under court supervision. This marked the end of operations as an independent public entity.

Delisting from Nasdaq and Trading Status

Nasdaq suspended trading of Tabula Rasa HealthCare shares on January 23, 2023, after the firm failed to meet listing standards post-bankruptcy. Shares now trade over-the-counter under symbol TRHCQ, but volume is negligible. No active quotes appear on major platforms as of March 2026.

For verification, the primary venue was Nasdaq in USD prior to delisting. Current pink sheet trading sees bids near zero due to liquidation prospects. Investors cannot reliably buy or sell without deep discount broker access.

DACH platforms like Consorsbank or Comdirect may show holdings but no live pricing. This stasis persists three years post-filing, signaling permanent value impairment.

Bankruptcy Proceedings and Asset Sales

The Delaware bankruptcy court oversaw a Section 363 sale process. CareMax acquired certain assets in March 2023 for $15 million plus assumption of liabilities. This included the MedWise platform, but not all IP or operations.

Remaining assets entered liquidation. Secured creditors, led by lenders like OrbiMed, recovered partial principal. Equity holders rank last, with distributions unlikely. Court documents confirm no value for common stock post-creditor payouts.

By 2026, the case nears closure with final distributions minimal. No recent filings indicate revival. Former employees and partners shifted to competitors like Omnicell or BD.

Why the Market Reacted Strongly in 2022-2023

Pre-bankruptcy, TRHC stock traded above $30 on Nasdaq in USD during 2021 peaks. News of distress triggered a 90% plunge within months. Investors fled as growth story unraveled into solvency crisis.

Broader context included Fed rate hikes squeezing leveraged tech firms. Healthcare IT faced reimbursement pressures and labor shortages. Tabula Rasa's high R&D burn without profitability amplified vulnerabilities.

Analyst coverage ceased post-delisting. Short interest had spiked earlier, reflecting doubts on debt refinancing. The episode underscored risks in acquisitive SaaS models during downturns.

Relevance for DACH Investors

German-speaking investors often hold U.S. small-caps via ETFs or direct brokerage. Tabula Rasa entered portfolios chasing digital health growth. Bankruptcy wiped out such bets, mirroring losses in peers like SmileDirectClub.

DACH funds emphasize governance and liquidity. This case warns against overleveraged U.S. names. European medtech like Siemens Healthineers offers stabler alternatives with diversified revenue.

Tax implications arise for holdings in tax-advantaged accounts. German Abgeltungsteuer applies to total loss claims. Austrian and Swiss investors should consult advisors on write-offs amid zero recovery outlook.

Risks and Lessons from the Collapse

Key risk was debt overhang in a rising rate environment. Tabula Rasa's net debt exceeded 5x EBITDA at distress onset. M&A integration failed to deliver synergies promptly.

Operational challenges included client churn as competitors advanced AI-driven tools. Regulatory hurdles in pharmacogenomics added compliance costs. The firm underestimated macro headwinds.

Lessons for investors: Scrutinize balance sheets in growth stocks. Favor cash-generative models over debt-fueled expansion. Monitor covenant breaches early.

Sector Context and Future Outlook

Medication management remains vital amid aging populations. Survivors like Cerner (now Oracle) consolidate market share. AI integration promises efficiency gains.

For Tabula Rasa remnants, no standalone revival expected. Assets enhance buyers' offerings. Equity likely worthless indefinitely.

DACH investors should pivot to resilient EU players. Watch U.S. filings for similar distress signals in health IT.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.